325 related articles for article (PubMed ID: 9020487)
1. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Body JJ; Dumon JC; Gineyts E; Delmas PD
Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of pamidronate in patients with metastatic bone disease.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
Br J Cancer; 1996 May; 73(9):1089-95. PubMed ID: 8624269
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
[TBL] [Abstract][Full Text] [Related]
5. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
Coleman RE; Houston S; James I; Rodger A; Rubens RD; Leonard RC; Ford J
Br J Cancer; 1992 May; 65(5):766-8. PubMed ID: 1586605
[TBL] [Abstract][Full Text] [Related]
6. Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
Body JJ; Dumon JC; Piccart M; Ford J
J Bone Miner Res; 1995 Aug; 10(8):1191-6. PubMed ID: 8585422
[TBL] [Abstract][Full Text] [Related]
7. Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate.
Dodwell DJ; Howell A; Ford J
Br J Cancer; 1990 Jan; 61(1):123-5. PubMed ID: 2297483
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
Glover D; Lipton A; Keller A; Miller AA; Browning S; Fram RJ; George S; Zelenakas K; Macerata RS; Seaman JJ
Cancer; 1994 Dec; 74(11):2949-55. PubMed ID: 7525038
[TBL] [Abstract][Full Text] [Related]
9. Markers of bone resorption in patients treated with pamidronate.
Lipton A; Demers L; Curley E; Chinchilli V; Gaydos L; Hortobagyi G; Theriault R; Clemens D; Costa L; Seaman J; Knight R
Eur J Cancer; 1998 Dec; 34(13):2021-6. PubMed ID: 10070304
[TBL] [Abstract][Full Text] [Related]
10. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
11. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.
Vinholes JJ; Purohit OP; Abbey ME; Eastell R; Coleman RE
Ann Oncol; 1997 Dec; 8(12):1243-50. PubMed ID: 9496390
[TBL] [Abstract][Full Text] [Related]
12. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans.
Rosen HN; Moses AC; Gundberg C; Kung VT; Seyedin SM; Chen T; Holick M; Greenspan SL
J Clin Endocrinol Metab; 1993 Sep; 77(3):664-9. PubMed ID: 8370687
[TBL] [Abstract][Full Text] [Related]
13. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
14. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia.
Body JJ; Delmas PD
J Clin Endocrinol Metab; 1992 Mar; 74(3):471-5. PubMed ID: 1740478
[TBL] [Abstract][Full Text] [Related]
15. Bone metastases and tumor-induced hypercalcemia.
Body JJ
Curr Opin Oncol; 1992 Aug; 4(4):624-31. PubMed ID: 1511019
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease.
Engler H; Koeberle D; Thuerlimann B; Senn HJ; Riesen WF
Clin Chem Lab Med; 1998 Nov; 36(11):879-85. PubMed ID: 9877095
[TBL] [Abstract][Full Text] [Related]
17. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell AJ; Markham A
Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
[TBL] [Abstract][Full Text] [Related]
18. Assessment of different markers of bone resorption in postmenopausal osteoporotic women treated with pamidronate.
Kollerup G; Sørensen HA; Hyldstrup L; Storm T
Scand J Clin Lab Invest; 1997 Oct; 57(6):479-86. PubMed ID: 9350066
[TBL] [Abstract][Full Text] [Related]
19. Treatment of tumor-induced osteolysis by APD.
Burckhardt P; Thiébaud D; Perey L; von Fliedner V
Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
[TBL] [Abstract][Full Text] [Related]
20. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.
Rosen HN; Dresner-Pollak R; Moses AC; Rosenblatt M; Zeind AJ; Clemens JD; Greenspan SL
Calcif Tissue Int; 1994 Jan; 54(1):26-9. PubMed ID: 8118749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
